Mesoblast Limited (NASDAQ:MESO - Get Free Report)'s share price passed below its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $13.90 and traded as low as $10.38. Mesoblast shares last traded at $10.51, with a volume of 174,166 shares trading hands.
Analyst Upgrades and Downgrades
Separately, Cantor Fitzgerald upgraded shares of Mesoblast to a "strong-buy" rating in a research note on Monday, March 31st. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, two have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, Mesoblast presently has a consensus rating of "Moderate Buy" and an average price target of $18.00.
Read Our Latest Analysis on MESO
Mesoblast Stock Up 4.9%
The company has a debt-to-equity ratio of 0.22, a quick ratio of 0.63 and a current ratio of 0.96. The firm has a 50 day moving average price of $11.24 and a 200-day moving average price of $13.90.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently bought and sold shares of MESO. Bank of America Corp DE grew its position in Mesoblast by 1,503.3% in the 4th quarter. Bank of America Corp DE now owns 290,728 shares of the company's stock worth $5,756,000 after purchasing an additional 272,595 shares during the last quarter. Goldman Sachs Group Inc. acquired a new stake in Mesoblast during the first quarter worth about $3,209,000. Oaktree Capital Management LP bought a new position in Mesoblast during the fourth quarter valued at about $3,556,000. GAMMA Investing LLC raised its holdings in Mesoblast by 1,174.2% in the 1st quarter. GAMMA Investing LLC now owns 85,513 shares of the company's stock valued at $1,067,000 after acquiring an additional 78,802 shares in the last quarter. Finally, Summit X LLC raised its holdings in Mesoblast by 36.0% in the 1st quarter. Summit X LLC now owns 198,163 shares of the company's stock valued at $2,473,000 after acquiring an additional 52,508 shares in the last quarter. 1.43% of the stock is currently owned by institutional investors and hedge funds.
About Mesoblast
(
Get Free Report)
Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.
Featured Articles
Before you consider Mesoblast, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Mesoblast wasn't on the list.
While Mesoblast currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
